目的 探討鎮(zhèn)心痛口服液聯(lián)合單硝酸異山梨酯治療冠心病心絞痛的臨床療效。方法 選取2022年7月—2023年10月武漢市中醫(yī)醫(yī)院收治的86例冠心病心絞痛患者，依據(jù)用藥情況將所有患者分為對照組和治療組，每組各43例。對照組患者口服單硝酸異山梨酯緩釋片，40 mg/次，1次/d。治療組在對照組的治療基礎上口服鎮(zhèn)心痛口服液，20 mL/次，3次/d。兩組用藥12周觀察治療情況。觀察兩組的臨床療效和癥狀緩解時間，比較兩組治療前后西雅圖心絞痛評分量表（SAQ）評分、歐洲五維健康生活質量問卷量表（EQ-5D）評分、血管性假血友病因子（vWF）、同型半胱氨酸（Hcy）、一氧化氮（NO）、P-選擇素水平的變化情況。結果 治療后，治療組總有效率是95.35%，顯著高于對照組的79.07%（P＜0.05）。治療后，治療組患者胸悶、胸痛、心悸、體力不支緩解時間均顯著短于對照組（P＜0.05）。治療后，兩組心絞痛持續(xù)時間、發(fā)作次數(shù)均較同組治療前顯著降低（P＜0.05）；治療后，治療組心絞痛持續(xù)時間、發(fā)作次數(shù)均低于對照組（P＜0.05）。治療后，兩組SAQ評分、EQ-5D評分均顯著提高（P＜0.05）；治療后，治療組SAQ評分、EQ-5D評分均高于對照組（P＜0.05）。治療后，兩組血清Hcy、vWF、P-選擇素水平均顯著降低，而NO顯著升高（P＜0.05）；治療后，治療組Hcy、vWF、P-選擇素水平均低于對照組，NO水平高于對照組（P＜0.05）。結論 鎮(zhèn)心痛口服液聯(lián)合單硝酸異山梨酯治療冠心病心絞痛具有較好的臨床療效，能有效改善患者臨床癥狀，減弱機體炎性反應，提升患者生活質量，值得借鑒與應用。

Objective To investigate the therapeutic effect of Zhenxintong Oral Liquid combined with isosorbide mononitrate in treatment of angina pectoris. Methods A total of 86 patients with angina pectoris with coronary heart disease admitted to Wuhan Traditional Chinese Medicine Hospital from July 2022 to October 2023 were selected. According to drug use, all patients were divided into control group and treatment group, with 43 cases in each group. Patients in control group were po administered with Isosorbide Mononitrate Sustained-Release Tablets, 40 mg/time, once daily. Patients in treatment group were po administered with Zhenxintong Oral Liquid on the basis of the control group, 20 mL/time, three times daily. The two groups were treated for 12 weeks to observe the treatment. The clinical efficacy and symptom remission time of two groups were observed, and the changes of the Seattle Angina Rating Scale (SAQ) score, the European five-dimension Health Quality of Life Questionnaire (EQ-5D) score, vascular pseudomelophiliac factor (vWF), homocysteine (Hcy), nitric oxide (NO), and P-selectin levels before and after treatment were compared between two groups. Results After treatment, the total effective rate of treatment group was 95.35%, which was significantly higher than that of control group (79.07%, P < 0.05). After treatment, the relief time of chest tightness, chest pain, palpitation and physical inactivity in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, the duration and frequency of angina pectoris in 2 groups were significantly decreased compared with before treatment (P < 0.05). After treatment, the duration and frequency of angina pectoris in treatment group were lower than those in control group (P < 0.05). After treatment, SAQ score and EQ-5D score were significantly increased in both groups (P < 0.05). After treatment, SAQ scores and EQ-5D scores in treatment group were higher than those in control group (P < 0.05). After treatment, serum Hcy, vWF and P-selectin levels in 2 groups were significantly decreased, but NO levels were significantly increased (P < 0.05). After treatment, the levels of Hcy, vWF and P-selectin in treatment group were lower than those in control group, and the level of NO was higher than that in control group (P < 0.05). Conclusion Zhenxintong Oral Liquid combined with isosorbide mononitrate has good clinical efficacy in treatment of angina pectoris, and can effectively improve the clinical symptoms of patients, weaken the inflammatory response of the body, and improve the life quality, which is worth learning and application.

R972

湖北省自然科學基金資助項目（2022CFC002）